This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jensen: A Pair of Healthy Generic Drug Makers

Overall prescription drug spending in the U.S. rose 1%, year over year, in May, its strongest month of growth of 2012. Generic drugs posted a much better growth rate of 5% offsetting the 16% decline in branded drugs. I like the generic drug sector at current valuations and have a couple in my portfolio. Generics have several long-term tailwinds in their favor:

A. The aging of the population in developed countries.

B. Huge new markets coming online in the emerging economies.

C. The constraints in Western government's budgets, providing a large incentive to move to generics paid for by government programs.

D. A significant amount of blockbuster branded drugs coming off patent over the next several years.

These secular trends have led Credit Suisse to project generics will account for 89% of all drug prescriptions in 2021 from 77% today. Here are two generic drug makers that look good right now based on valuation and long-term prospects.

Mylan (MYL - Get Report) is a worldwide generic (91% of total revenues) and branded drug maker with a market cap of just over $9 billion.

Four reasons MYL delivers good value at $21 a share:

  • The stock is selling at the bottom of its five-year valuation range based on P/B, P/E and P/CF.
  • The company has pursued strategic acquisitions that have allowed it to increase revenues at an annual clip north of 22% over the past five years. It has several key products including an epinephrine auto-injector with more than 95% market share in the U.S. In addition, 30% of worldwide HIV patients use a Mylan product.
  • Mylan has done a solid job of reducing the debt incurred for these acquisitions over the past few years and has grown its adjusted EBITDA at an average 17.5% yearly clip over the preceding four years.
  • The company has exceeded earnings estimates each of the last four quarters and consensus earnings estimates for FY2012 and FY2013 have ticked up over the last two months. MYL sells for a forward PE of under 8, a significant discount to its five-year average (14.4).

Teva Pharmaceuticals (TEVA - Get Report) is the largest generic drug maker in the world and is based in Israel.

Four reasons TEVA is a solid long-term value pick for patient investors at $38 a share:

  • The company has been hit hard by worries about the expiration of its best-selling drug, Copaxone, as well as recently reduced guidance. However, as it is trading at just 6.5 forward earnings, the bad news appears fully priced into the stock.
  • The company has a well-respected new CEO, who should serve as a long-term catalyst and change agent for the company and the stock. Easing of the situation in Iran also should reduce the "Israel" discount hanging over TEVA as well.
  • The stock sells at the very bottom of its five-year valuation range based on P/E, P/S, P/CF and P/B. TEVA also yields 2.1%.
  • The median analysts' price target is $51 a share for the 20 analysts who cover Teva Pharmaceuticals. The stock also appears to have technical support just under current price levels.
At the time of publication, Jensen was long MYL and TEVA.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs